31-valent pneumococcal conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Vaxcyte, Inc.

Conditions

Pneumococcal Vaccines

Phase 3

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Active, not recruitingNCT07365826

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2026-01-12End: 2027-03-01Updated: 2026-03-31

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

RecruitingNCT07425392

Vaxcyte, Inc.Pneumococcal Vaccines

Start: 2026-02-09End: 2027-03-01Target: 720Updated: 2026-03-18